Is AOD-9604 FDA approved? What the record actually shows

Last updated 2026-07-25

Is AOD-9604 FDA approved for weight loss or any other use?

No. Search Drugs@FDA, the government's own database of every approved drug product, and AOD-9604 doesn't show up because it was never granted approval for any indication ^[1]. There's no NDA, no BLA, nothing. That's the whole answer to the headline question, but it's worth sitting with for a second because a lot of sales copy around this peptide implies otherwise or just stays vague on purpose. AOD-9604 started life as a Phase II obesity candidate developed by an Australian biotech (Metabolic Pharmaceuticals) in the early 2000s. It reached human obesity trials, which is farther than most peptides sold online ever get. But reaching Phase II and getting approved are two completely different things, and this compound stalled at the first one. A 2004 review of the compound in Current Opinion in Investigational Drugs covers its metabolic profile and clinical development status at that stage, and the trail more or less goes cold in the peer-reviewed record after that ^[2]. A 2006 survey of obesity drugs in clinical development listed AOD-9604 among the pipeline candidates of that era, alongside plenty of other molecules that also never made it to market ^[3]. If you want the one-line version for a friend: it's an unapproved, investigational peptide with a stalled trial history, not a licensed weight-loss drug.

What is AOD-9604 supposed to do, and does the fragment idea make sense?

AOD-9604 is a synthetic fragment of human growth hormone, specifically the C-terminal region (roughly amino acids 176-191) that researchers identified as the part responsible for HGH's fat-metabolizing effects without the growth-promoting effects that come from the rest of the molecule. The idea, on paper, is clever: take the piece of HGH that might drive lipolysis, leave behind the piece that drives cell growth and the side effects that worry people (fluid retention, joint pain, insulin resistance, potential tumor-growth concerns). That's a reasonable hypothesis to test. It just isn't the same thing as a hypothesis that panned out. The fragment approach has a certain elegance, which is probably why it got funded for Phase II trials in the first place. But elegant biology doesn't guarantee clinical results, and elegance is not evidence. More recent literature treats AOD-9604 as part of a broader category of unapproved peptides used off-label in sports medicine and musculoskeletal contexts rather than as a validated obesity therapy. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedic applications and the regulatory and evidentiary challenges around several of them, including unapproved peptides in this general class ^[4]. A companion 2026 paper in Sports Medicine on peptide therapies for musculoskeletal injuries and athletic performance reviews safety and efficacy data across a range of approved and unapproved peptides, again treating fragment-based products as unapproved and evidentially thin compared to licensed drugs ^[5].

What did the human obesity trials actually find?

This is the part that gets buried in most sales copy, so here it is straight: AOD-9604 went through obesity trials in humans, and the weight-loss results did not separate convincingly from placebo. That's the central fact about this compound's clinical history, and any page that doesn't say it plainly isn't being straight with you. The compound reached Phase IIb testing under Metabolic Pharmaceuticals in the mid-2000s, and it was covered in the trial-tracking literature of that period, including entries in the Methods and Findings in Experimental and Clinical Pharmacology "Gateways to Clinical Trials" series that logged its progress through the development pipeline in 2003 and 2005 ^[6][7][8]. Those gateway reports function as a running index of what's moving through trials industry-wide; they aren't itself proof of efficacy, they're a record that a trial existed and was being tracked. What's missing is the thing you'd want to see if this were a success story: a published Phase III result, an FDA submission, or a follow-up program that picked the compound back up after Phase II and pushed it forward. None of that happened. The 2004 review of its metabolic profile is the most substantive peer-reviewed look at the compound's biological activity that's easy to find ^[2], and the trail of clinical development effectively ends not long after the mid-2000s Phase II work referenced in the trial gateway records. When a genuinely positive Phase II obesity result exists, companies chase it hard because the market for an effective, growth-hormone-side-effect-free fat-loss drug is enormous. Nobody chased this one further. Read that as data.

Why did AOD-9604 stall in development?

Nobody published a clean "here's exactly why it failed" postmortem that's easy to point to, which is itself part of the problem. What we have is the trial-tracking record showing it moving through Phase II gateways in 2003 and 2005 ^[6][7][8] and then no forward momentum into Phase III or an approval filing. The most honest interpretation, given the public record, is that the efficacy signal wasn't strong enough to justify the cost of a Phase III program, or the sponsor's finances or strategic priorities changed, or both. Small biotechs run out of money and shift focus constantly; that alone doesn't prove a drug doesn't work. But it also doesn't prove it does, and in the absence of a positive Phase III result or an approval, the honest conclusion is that the human obesity data available in the literature doesn't support a real weight-loss effect over placebo. If you're weighing this against something with a harder efficacy signal, it's worth comparing the fragment approach against a full growth hormone secretagogue like tesamorelin, which does have FDA approval for a specific indication (HIV-associated lipodystrophy) and a completed Phase III record behind it. See our AOD-9604 vs tesamorelin comparison for how the trial records actually stack up side by side.

Can AOD-9604 legally be compounded by a US pharmacy?

No, not for human use, based on the current FDA bulk substance lists. Compounding pharmacies in the US operate under two legal pathways: 503A (traditional compounding for an individual patient with a prescription) and 503B (outsourcing facilities that compound in larger batches). Both pathways require the active ingredient to either be an FDA-approved drug component or to appear on FDA's specific bulks list for that pathway. The 503A bulks list is codified at 21 CFR 216.23, and the current 503B bulks list is at 21 CFR 216.24 ^[9][10]. AOD-9604 is not an FDA-approved drug (as established above) and it does not appear on either bulks list as maintained by FDA ^[11][12]. The legal framework for 503A compounding itself comes from 21 U.S.C. 353a ^[13]. That means a US compounding pharmacy has no lawful basis to compound AOD-9604 as a drug for a human patient, prescription or not. Anything labeled or marketed for human ingestion, injection, or therapeutic use in that framework is operating outside the rules FDA has published. This is distinct from products sold under a "research use only" label, which is a separate (and separately murky) category covered under FDA's general framework for intended use determinations at 21 CFR 201.128 ^[14]. If a seller is telling you a compounding pharmacy can legally make this for you as a prescription weight-loss drug, ask them to point to where it's on the 503A or 503B list, because it currently isn't.

Is AOD-9604 banned in sports, and can it be detected in drug testing?

It's grouped with growth hormone and growth hormone fragments in anti-doping frameworks, which generally treat these as prohibited substances in competitive sport, and detection science has moved specifically to close loopholes around fragments like this one. A notable finding here: AOD-9604 does not interfere with the WADA hGH isoform immunoassay, the standard test labs use to detect growth hormone doping, according to a 2013 study in Drug Testing and Analysis ^[15]. That matters because it confirms the immunoassay isn't fooled or diluted by the presence of the fragment, closing off a theoretical loophole where someone might have hoped the fragment would mask HGH use. Separately, analytical chemists have built out dedicated methods to catch AOD-9604 and similar small peptides directly. A 2014 review in the Journal of Pharmaceutical and Biomedical Analysis covers detection approaches for emerging, non-approved doping substances including small peptides in this class ^[16]. A 2014 review in Expert Review of Proteomics specifically discusses detecting peptidic drugs, drug candidates, and their analogs, including fragment-type peptides, in doping control ^[17]. And a 2016 method published in the Journal of Separation Science describes a technique using direct urine injection with liquid chromatography and ion mobility mass spectrometry built to screen for peptides under 2 kDa, a category that includes AOD-9604 given its small fragment size ^[18]. Testing labs are not behind on this one.

What are people actually buying when they buy "AOD-9604" online?

Almost always a research chemical, sold labeled "not for human consumption," from a supplier operating outside FDA's drug approval and compounding frameworks entirely. This isn't a pharmaceutical-grade product with a chain of custody back to an approved manufacturing process, because no such process exists for this compound in the US. Quality and purity vary enormously across suppliers in this space, and because none of it goes through FDA drug manufacturing oversight, there's no regulatory backstop checking what's actually in the vial. If you're going to research this compound at all, the practical questions become: does the seller publish third-party certificates of analysis, do they name the testing lab, and is there a provider-reviewed path rather than an anonymous storefront. Our AOD-9604 peptide for sale guide and best place to buy AOD-9604 page cover what to check before buying anything in this category, provider-reviewed and fulfilled through a named pharmacy partner rather than an unverified retailer. For readers who want the deeper look at the underlying biology and the full trial history in one place rather than scattered across studies, our AOD-9604 peptide overview walks through the mechanism claims against what's actually been published.

How does AOD-9604's evidence compare to other GH-related peptides?

AOD-9604 sits at the weak end of the evidence spectrum compared to peptides that actually completed Phase III trials and received approval for a defined indication.

The contrast is the point. Tesamorelin and the GLP-1 drugs went all the way through the approval pipeline with published Phase III data supporting their specific indications. AOD-9604 didn't. That doesn't mean AOD-9604's fragment mechanism was nonsense as a hypothesis, but it does mean the human evidence never reached the bar that regulators or serious clinical programs require before calling something an effective weight-loss treatment. If you're deciding between researching AOD-9604 versus a peptide with a completed approval pathway, the trial record itself should do most of the deciding for you. See the full AOD-9604 vs tesamorelin breakdown for indication-by-indication detail.

Does AOD-9604 have any FDA-recognized safety data?

Some early-phase safety data exists from its Phase II development, but nothing that constitutes an FDA safety review, because the compound was never submitted for or granted approval, and FDA doesn't publish independent safety assessments for drugs that were never submitted through an approval pathway. What exists in the literature is limited to what sponsors and independent researchers have published: the 2004 metabolic profile review ^[2], mentions in obesity-pipeline surveys ^[3], and more recent framework discussions in orthopaedic and sports-medicine peptide reviews that treat it as an unapproved compound requiring more rigorous study before any safety conclusions can be drawn ^[4][5]. None of that is equivalent to an FDA-reviewed safety package, which typically includes controlled trials at defined doses, systematic adverse event tracking, and a risk-benefit determination made by agency reviewers. That process never happened here because the drug was never submitted for it.

So what's the honest bottom line on AOD-9604?

It's an unapproved research compound with a real but incomplete scientific rationale, a Phase II trial history that stalled without a positive follow-through, and no lawful compounding pathway in the US as things currently stand. The fragment hypothesis, that you could isolate HGH's fat-metabolizing region and skip the side-effect-driving growth region, was worth testing, and it got tested. The obesity trials it went through didn't produce weight-loss results that separated convincingly from placebo, and the compound was never pushed to Phase III or filed for approval. That's not a smear, that's just what the record shows when you follow it from the 2004 metabolic review ^[2] through the mid-2000s trial gateway logs ^[6][7][8] and into the current absence of any FDA listing ^[1] or bulk substance status ^[11][12]. At AOD-9604 Co, we cover this compound because people are researching it and deserve a straight answer, not because we think it clears the bar that approved obesity drugs have cleared. If you're going to look at it at all, look at it through a provider-reviewed route with a named pharmacy partner handling fulfillment, not an anonymous vial from an unverified seller, and go in knowing the trial record, not the marketing copy, is what should set your expectations.

Frequently asked questions

Is AOD-9604 FDA approved for fat loss?

No. AOD-9604 has never received FDA approval for fat loss or any other indication. Drugs@FDA, the agency's database of approved drug products, has no listing for it because no NDA or BLA was ever approved for this compound.

Has AOD-9604 completed Phase III clinical trials?

No. Available records show AOD-9604 reached Phase IIb testing in the mid-2000s, tracked in trial gateway reports from 2003 and 2005, but there's no published Phase III result and no evidence the program advanced past Phase II.

Did AOD-9604 work better than placebo for weight loss in human trials?

The published record does not show a weight-loss effect that separated convincingly from placebo in AOD-9604's human obesity trials. That's the central reason development stalled and no approval was ever sought.

Can a US compounding pharmacy legally make AOD-9604?

Not for human use. AOD-9604 doesn't appear on FDA's 503A bulks list (21 CFR 216.23) or the 503B bulks list (21 CFR 216.24), so pharmacies compounding under either pathway have no legal basis to prepare it as a human drug.

Is AOD-9604 banned by anti-doping agencies?

Growth hormone fragments including AOD-9604 fall under anti-doping prohibitions on GH-related substances. Detection science, including dedicated LC-mass spectrometry methods for small peptides, has been specifically developed to catch this class of compound in testing.

Does AOD-9604 show up on the standard hGH doping test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not interfere with the WADA hGH isoform immunoassay, meaning the standard growth hormone detection test isn't fooled or masked by the fragment's presence.

What is AOD-9604 supposed to do biologically?

It's a synthetic fragment of human growth hormone's C-terminal region, hypothesized to retain the fat-metabolizing activity of HGH while leaving out the growth-promoting region responsible for many HGH side effects. The hypothesis was tested in Phase II trials; it didn't produce a convincing weight-loss effect over placebo.

Why did AOD-9604 never get approved?

The public record doesn't include a formal failure explanation, but the pattern is clear: it advanced through Phase II gateway tracking in 2003 and 2005 and then simply stopped progressing, with no Phase III publication or approval filing following.

Is AOD-9604 the same thing as HGH?

No. It's a small fragment (roughly amino acids 176-191) of the full HGH molecule, not the whole hormone. The idea was to isolate one region's activity, not to replicate HGH's full effect.

Is it legal to buy AOD-9604 online in the US?

Products are typically sold labeled 'not for human consumption' as research chemicals, operating outside FDA's approval and compounding frameworks. That labeling reflects its actual regulatory status: it isn't an approved or lawfully compoundable human drug.

How does AOD-9604 compare to tesamorelin's evidence base?

Tesamorelin completed Phase III trials and holds FDA approval for HIV-associated lipodystrophy. AOD-9604 stalled at Phase II with no convincing efficacy signal and no approval. See our AOD-9604 vs tesamorelin comparison for the full breakdown.

Are there any FDA safety warnings specific to AOD-9604?

FDA doesn't publish safety reviews for drugs that were never submitted through an approval pathway, and AOD-9604 was never submitted. Any safety data available comes from limited published research rather than an FDA-reviewed safety package.

Sources

1. FDA, Drugs@FDA database: AOD-9604 has no listed approval of any kind in FDA's database of approved drug products
2. Current Opinion in Investigational Drugs, 2004 (PMID 15134286): 2004 review covers AOD-9604's metabolic profile and clinical development status at that stage
3. Current Opinion in Investigational Drugs, 2006 (PMID 16625817): 2006 survey of obesity drugs in clinical development lists AOD-9604 among pipeline candidates of that era
4. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptides in orthopaedic applications and regulatory challenges around unapproved peptides in this class
5. Sports Medicine (Auckland), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
6. Methods and Findings in Experimental and Clinical Pharmacology, 2003 (PMID 14685303): Trial gateway report tracking AOD-9604's progress through clinical development pipeline in 2003
7. Methods and Findings in Experimental and Clinical Pharmacology, 2003 (PMID 14571286): Second 2003 trial gateway entry logging AOD-9604's clinical trial status
8. Methods and Findings in Experimental and Clinical Pharmacology, 2005 (PMID 15834452): 2005 trial gateway report showing continued Phase II tracking of AOD-9604 with no forward progression to Phase III
9. eCFR, 21 CFR 216.23: Defines the 503A bulk drug substances list that governs traditional pharmacy compounding
10. eCFR, 21 CFR 216.24: Defines the 503B bulk drug substances list that governs outsourcing facility compounding
11. FDA, bulk drug substances used in compounding under section 503A: AOD-9604 does not appear on FDA's current 503A bulk drug substances list
12. FDA, bulk drug substances nominated for use in compounding (current list): AOD-9604 is not included among substances approved for compounding use on FDA's current nomination list
13. Cornell Law, 21 U.S.C. 353a: Establishes the federal legal framework under which traditional pharmacy compounding (503A) operates
14. eCFR, 21 CFR 201.128: Defines how FDA determines a product's intended use, relevant to research-use-only labeling claims
15. Drug Testing and Analysis, 2013 (PMID 24124033): AOD-9604 does not influence or interfere with the WADA hGH isoform immunoassay used in anti-doping testing
16. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Reviews analytical detection approaches for emerging, non-approved therapeutics including small peptides in doping controls
17. Expert Review of Proteomics, 2014 (PMID 25382550): Reviews methods for detecting peptidic drugs, candidates, and analogs including fragment-type peptides in sports doping
18. Journal of Separation Science, 2016 (PMID 26578461): Describes a direct urine injection LC-ion mobility mass spectrometry method for screening peptides under 2 kDa, a category including AOD-9604